Cosmo Pharmaceuticals NV

COPN

Company Profile

  • Business description

    Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33.

  • Contact

    Sir John Rogerson’s Quay
    Riverside II
    Dublin2
    IRL

    T: +353 18170370

    E: [email protected]

    https://www.cosmopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    332

Stocks News & Analysis

stocks

2 ASX shares that benefit from sticky inflation

Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks

Our view of Dexus / Scentre deal

Dexus acquires stake in Westfiend Chermside.
stocks

Undervalued ASX retailer benefiting from rebound in spending

Uplift in sales momentum continues.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,923.807.50-0.08%
CAC 408,124.8856.260.70%
DAX 4024,229.9143.420.18%
Dow JONES (US)48,416.5641.49-0.09%
FTSE 1009,751.31102.281.06%
HKSE25,628.88347.91-1.34%
NASDAQ23,057.41137.76-0.59%
Nikkei 22550,168.11668.44-1.31%
NZX 50 Index13,394.5013.64-0.10%
S&P 5006,816.5110.90-0.16%
S&P/ASX 2008,635.008.90-0.10%
SSE Composite Index3,867.9221.42-0.55%

Market Movers